The 15th Middle East Best of San Antonio
Breast Cancer Symposium
5-7 February 2021, Al Faisal University Riyadh
The Organizing and Scientific Committee of the 15th Middle East Best of San Antonio Breast Cancer Symposium and the Oncology Department of King Khalid University and AlFaisal University , Riyadh welcomes you to the 15th Middle East Best of SABCS™. This is also the 43nd year of the San Antonio Breast Cancer Symposium (SABCS™) in San Antonio, Texas, USA. The symposium is the premier conference for basic, translational, and clinical cancer research professionals which provides a platform for interaction and communication among a wide range of researchers and healthcare professionals who has a special interest in breast cancer. It is well known for presenting the latest breast cancer data and updates from all over the world. The MESABCS allows healthcare professionals who are unable to travel to San Antonio, the opportunity to experience and discuss research and advances with colleagues and key opinion leaders. Attendees of the MESABCS program will receive the most current information on breast cancer research and advances that are changing clinical practice presented in the original format delivered at the meeting in San Antonio, Texas, this year.
This conference is accredited with CME hours by the Saudi Council for Health Specialties (SCFHS). On behalf of the Organizing and Scientific Committees of 15th MESABCS, we are delighted to invite you to become a part of this event and we will greatly appreciate your presence.
We look forward to welcoming you in Riyadh!
ABOUT THE CONFERENCE
The 15th Middle East Best of San Antonio Breast Cancer Symposium (15th MESABCS) allows healthcare professionals, the opportunity to experience and discuss the research and advances with colleagues and key opinion leaders. Hence, the attendees of the 15th MESABCS program will receive the most current information on breast cancer research presented in the original format delivered at the meeting in San Antonio in December 2020. Moreover, they will learn of the current advances in breast cancer research that are changing clinical practice for the benefit of the patients.
Breast pathology update
Breast cancer screening – Triple negative breast cancer – Targeted therapy – Metastatic breast cancer – Loco-regional surgery – Radiation therapy – Supportive special issue
Medical Oncologists – Clinical Oncologist – Radiation Oncologists – Radiologists – Surgeons – Fellows – Pharmacist – Technicians – Nurses
This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.
Location: Hall 1, Building A , Golden Street , Southafrica
11:05 – 12:00
Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A